Visalytics
Visalytics
approved EB-2 (NIW)

Associate Professor

Pharmacology · Iran · 2025-02-20

Processing Time
119 days
Decision Date
2025-02-20
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Proposed Endeavor

The petitioner proposes to design and apply innovative pharmaceutical agents as adjunctive therapies to conventional treatments for chronic neuropathic pain and mental health disorders. The work focuses on developing compounds with enhanced analgesic effects while minimizing dependency risks and investigating mechanisms to prevent morphine tolerance. Additionally, the endeavor aims to create targeted therapeutic approaches for depressive disorders with improved safety profiles.

Framework Evaluation

3 of 3 criteria met
1 Substantial Merit and National Importance Met

The research addresses critical healthcare challenges including chronic pain and mental health, which are areas of urgent national need.

2 Well-positioned to Advance the Endeavor Met

The petitioner's Ph.D. in pharmacology and extensive publication record of 49 articles and nearly 2,000 citations demonstrate they are uniquely prepared to advance the field.

3 Balance of Interests Met

The petitioner's demonstrated expertise and proven research impact make it beneficial to the U.S. to waive the labor certification requirement.

Why This Petition Was Approved

The petition was approved based on the petitioner's record of 49 peer-reviewed journal articles, 5 abstracts, and 1 book chapter, which garnered 1,942 citations. The evidence demonstrated that the petitioner's Ph.D. in pharmacology and history of high-impact research satisfy the Dhanasar prongs for national importance and being well-positioned. The broad recognition of their work by other scientists and clinicians further supported the waiver of the job offer requirement.

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Original Contributions

Similar Cases

Postdoctoral Researcher

Research and Development · South Korea

WeGreened EB-2 (NIW) approved
North Carolina 116 days 2022-10-08
The petitioner proposes to continue her research on identifying biomarkers and cognitive processes associated with chronic pain to develop improved monitoring and treatment methods. Her work focuses on the mechanisms of chronic pain and its effects on the body's reward center to create safer alternatives to opioids.
View Case

Research Scientist

Biotechnology · Nepal

WeGreened EB-2 (NIW) approved
Virginia 330 days 2025-05-13
The petitioner proposes to develop targeted gene therapies for chronic pain management by investigating cellular and molecular mechanisms in the brain. The work focuses on studying specific neural circuits and epigenetic pathways, such as circular RNAs and allele-specific enhancers, to address the root causes of pain perception and provide safer alternatives to opioids.
View Case

Associate Professor

Pharmaceuticals · Pakistan

WeGreened EB-2 (NIW) approved
487 days 2025-04-15
The petitioner proposes to design natural compound-based therapeutics using computer-aided drug discovery to treat Type 1 diabetes and neurological disorders. This work focuses on developing non-synthetic therapeutic options for inflammation-related disorders, chronic pain, and systemic conditions using bioactive compounds from traditional medicinal plants. The endeavor aims to improve patient outcomes and address significant public health concerns in the United States.
View Case

Others

Research and Development · Iran

WeGreened EB-2 (NIW) approved
North Carolina 8 days 2023-06-02
The petitioner proposes to conduct groundbreaking research into the rewarding and analgesic properties of opioid drugs and the role of various brain cell types in addiction. Her work also explores the potential of cannabinoid drugs to prevent neurological conditions such as epilepsy. The goal is to develop safer analgesics and innovative adjuvant therapies to directly address the national opioid crisis.
View Case

Frequently Asked Questions

A approved EB-2 NIW (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Pharmaceuticals cases More cases from Iran

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-02-20.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 119 days
Criteria Met 3 / 3
Evidence Types 3

EB-2 (NIW) Case Data

Scraped Case Data

Total Cases 3,814
Success Rate 53.6%
Sustained 2,046
Dismissed 1,672

Related Pages

EB-2 (NIW) Overview EB-2 (NIW) in Iran All EB-2 (NIW) Cases EB-2 (NIW) Dashboard Endeavor Search

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist